Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines

Published at Ottawa on September 11, 2024

Vital Submission to Shaping the Future: A Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines This submission comes at a critical juncture for the pharmaceutical distribution sector, whose future sustainability is at risk. As you will notice in our submission, CAPDM expresses concerns similar to those raised in previous rounds of consultation. If the Board’s ultimate concern is patient access, we are alarmed by the potential impact to access that the new guidelines will have on the drug distribution infrastructure in Canada, particularly for those in rural areas of the country. While we recognize the PMPRB's mandate and acknowledge the Board’s response that “provincially listed prices ultimately dictate the overall impact on supply chain issues,” we emphasize that these downstream effects stem from the PMPRB, as the listed prices are derived from the federally approved maximum drug price.